London
A breast cancer patient this week sued Britain’s National Health Service for refusing to give her a drug that could save her life. Elaine Barber, a 41-year-old mother of four, was told that prescribing Herceptin, a new drug that costs up to $50,000 a year per patient, was not “a cost-effective use of finite health resources.” Last month, though, a different patient was given the drug on the grounds that her status as a single mother of a disabled child rendered her case “exceptional.” In most E.U. countries, drugs are made available through public health systems as soon as they get an E.U. license. But in Britain, drugs must also undergo a cost-benefit analysis.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
Aug. 11 editorial cartoonsCartoons Monday’s political cartoons include solar power shunned by Donald Trump, Vladimir Putin's appetite for Ukraine, and another distraction from the Epstein files
-
Celebrating Cézanne in Aix-en-ProvenceThe Week Recommends The beautiful city is paying tribute to its most famous son with a series of cultural events
-
Sudoku medium: August 11, 2025The Week's daily medium sudoku puzzle
